PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders

FHS
May 22, 2024
5:58 am

PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKER™.

Irritable bowel syndrome not linked to higher Parkinson’s risk, study finds

Research investigates the association between irritable bowel syndrome (IBS) and Parkinson’s disease (PD), revealing that IBS is not linked to an increased overall risk of

April 1, 2024

Sanofi’s $1.7B rare disease gambit; CAR-T boxed warning saga; New biotechs on Nasdaq; A seller’s market for M&A?; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit

January 28, 2024

PharmaDrug CEO Provides Vision for Securedose Acquisition | Psychedelic Invest

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and

December 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.